Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
The non-covalent BTK space expands
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Sensei finds Faeth
The company buys in a PI3Kα and mTOR combo.
MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
